Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_provenance.
- befree-2016 importedOn "2016-02-19" NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_provenance.
- NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_assertion wasGeneratedBy ECO_0000203 NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_provenance.
- NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_assertion wasDerivedFrom befree-2016 NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_provenance.
- NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_assertion SIO_000772 18048643 NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_provenance.
- NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_assertion evidence source_evidence_literature NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_provenance.
- NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_assertion description "[Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_provenance.